- Funders and collaborators
- Latest news
- Publications Baseline
- Publications Follow-up
Aims of eGFR3
- What is the long-term change in kidney function since the first kidney health assessment in 2007-2011?
- Was there any major change in kidney function for people who were healthy, or had diabetes, or had mild-moderate kidney damage since the first kidney health assessment?
- What are common reasons people with kidney disease access hospital care?
- What are the impacts of an Indigenous-led eGFR3 study governance model for Aboriginal and Torres Strait Islander kidney health?
Aims of eGFR2
- To assess the evolution of kidney disease in an Indigenous Australian cohort from the regions of Australia with the greatest burden of End Stage Kidney Disease
- To perform community consultation and design appropriate interventions to reduce progression of chronic kidney disease in Indigenous Australians.
Aim of eGFR1
To determine an accurate and reliable test of kidney function in Aboriginal and Torres Strait Islander adults.
The eGFR study is a longitudinal study of kidney damage in a cohort of 600 Aboriginal and Torres Strait Islander adults from across the Northern Territory (NT), Western Australia (WA) and Far North Queensland.
Phase 1 of the study (2008-2011) assessed the accuracy of estimated measures of kidney function in Aboriginal and Torres Strait Islander adults. Determining the accuracy of measures of eGFR in this population with a high burden of chronic kidney disease is particularly important both to underline the validity of other clinical research and to confirm or modify current clinical practice, because levels of kidney function correspond to pathophysiological changes which determine current clinical care pathways.
Phase 2 of the study (2012-2014) assessed the progression of markers of kidney damage (urine protein and eGFR) in this high-risk cohort of Aboriginal and Torres Strait Islander adults. The latter part of Phase 2 will also involve design of interventions in collaboration with communities and service providers and based on our findings of key factors contributing to rapid progression of chronic kidney disease.
Phase 3 of the study (2020-2024) will partner researchers with community leaders and clinician leaders to report the long-term health outcomes and long-term changes in kidney function among Aboriginal and Torres Strait Islander adults who were previously assessed at baseline (between 2007- 2011), and follow-up (between 2012- 2015). Using a third direct health assessment and linkage to health datasets, the eGFR3 Study outcomes will inform the health action response needed for optimal and sustained kidney health among Aboriginal and Torres Strait Islander people.
Our research has found:
Phase 1 of this study validated the kidney function test for use in Aboriginal and Torres Strait Islander adults, known as the CKD-EPI eGFR blood test.
We reported this kidney function blood test was an accurate and reliable test of kidney function in Indigenous Australians, similar to reports that it is accurate and reliable in non-Indigenous Australians. We also showed that differences in body builds of Aboriginal and Torres Strait Islander adults, and between Indigenous and non-Indigenous Australians did not affect the accuracy of the kidney function blood test.
Since 2012, health professionals have been confidently using the kidney function test nationwide.
Chief investigator eGFR3
Chief investigator eGFR2 and eGFR1
- TBA (we will soon be advertising for the project manager for the eGFR3 study)
- eGFR1 Study (2008-2011)
- eGFR2 Study (2012-2014)
- eGFR3 Study (2020-2024)
- National Health and Medical Research Council (NHMRC).
- Austin Health
- University of Melbourne
- University of Queensland.
- Barr EL, Maple-Brown LJ, Barzi F, Hughes JT, Jerums G, Ekinci EI, Ellis AG, Jones GR, Lawton PD, Sajiv C, Majoni SW, Brown AD, Hoy WE, O'Dea K, Cass A, MacIsaac RJ. Comparison of creatinine and cystatin C based eGFR in the estimation of glomerular filtration rate in Indigenous Australians: The eGFR Study. Clinical Biochemistry 2016 Nov 25. pii: S0009-9120(16)30377-0 [Epub ahead of print]
- Hughes, Maple-Brown, Thomas, Lawton, Sinha, Cass, Barzi, Jones, Jerums, MacIsaac, O'Dea, Hoy. Cross-sectional associations of albuminuria among Aboriginal and Torres Strait Islander adults: the eGFR Study. Nephrology November 2016, doi: 10.1111/nep.12956
- Hughes JT, K O’Dea, K Piera, F Barzi, A Cass, WE Hoy, RJ MacIsaac, LJ Maple-Brown. Associations of serum adiponectin with markers of cardio-metabolic disease risk in Indigenous Australian adults with good health, diabetes and chronic kidney disease. Obes Res Clin Prac, 2016 Nov - Dec;10(6):659-672.
- Ekinci E, Hughes J, Chatfield M, Lawton PD, Jones GRD, Ellis A, Cass A, Thomas M, MacIsaac RJ, O'Dea K, Jerums G, Maple-Brown L. Hyperfiltration in Indigenous Australians with and without diabetes. Nephrology, Dialysis, Transplantation, 2015 Nov; 30(11):1877-84.
- Maple-Brown L, Hughes J, Chatfield M, Ward LC, Piers LS, Jones GD, Lawton P, Ellis AE, Cass A, Hoy W, O’Dea K, MacIsaac R, Jerums G. Adding Measures of Body Composition to the CKD-EPI GFR Estimating Equation in Indigenous Australians: The eGFR Study. American Journal of Kidney Diseases, 2015, Apr; 65(4):632-4.
- Maple-Brown LJ, Ekinci EI, Hughes JT, Chatfield M, Lawton PD, Jones GRD, et al. Performance of formulas for estimating Glomerular Filtration Rate in Indigenous Australians with and without Type 2 diabetes: The eGFR Study. Diabetic Medicine, 2014, 31(7):829-38.
- Maple-Brown LJ, Hughes JT, Lawton PD, Jones GR, Ellis AG, Drabsch K, Brown AD, Cass A, Hoy WE, Macisaac RJ, O'Dea K, Jerums G. Accurate Assessment of Kidney Function in Indigenous Australians: the eGFR Study. American Journal of Kidney Diseases, 2012; 60(4): 680-2.
- Maple-Brown L, P Lawton, J Hughes, SK Sharma, G Jones, A Ellis, W Hoy, A Cass, R MacIsaac, A Sinha, M Thomas, LS Piers, L Ward, K Drabsch, S Panagiotopoulos, R McDermott, K Warr, S Cherian, A Brown, G Jerums, K O’Dea. Study Protocol - Accurate assessment of kidney function in Indigenous Australians: aims and methods of the eGFR Study. BMC Public Health 2010; 10:80.
- Louise J Maple-Brown, Jaquelyne T Hughes, Rebecca Ritte, Federica Barzi, Wendy Hoy, Paul D Lawton, Graham RD Jones, Elizabeth Death, Alison Simmonds, Ashim Sinha, Sajiv Cherian, Mark AB Thomas, Robyn McDermott, Alex Brown, Kerin O’Dea, George Jerums, Alan Cass, Richard J MacIsaac. Progression of kidney disease in Indigenous Australians: The eGFR Follow-up Study. Clinical Journal of the American Society of Nephrology (CJASN), 2016 June 6;11(6):993-1004.
- Barr ELM, Barzi F, Hughes JT, Jerums G, O’Dea K, Brown A, Ekinci EI, Jones GRD, Lawton PD, Sinha A, Richard J MacIsaac RJ, Cass A, Maple-Brown LJ. The contribution of cardio-metabolic risk factors to estimated glomerular filtration rate (eGFR) decline in Indigenous Australians with and without albuminuria– the eGFR follow-up. Nephrology (accepted 14 May 2017).
Menzies School of Health Research Associate Prof Hughes received the 2019 NHMRC Clinical Trials and Cohort Studies Award for the top-ranked application in the 2019 funding round at NHMRC’s annual awards in Canberra.
In this edition of eGFR Study News, we summarise the key 2019 activities of the study team.
$6 million in research funding for three Indigenous health grants in the Northern Territory. This includes $2.5 million for an NHMRC Centre of Research Excellence at the Menzies School of Health Research to prevent and manage bronchiectasis, a lung disease which results in recurrent chest infections and is particularly common in Aboriginal and Torres Strait Islander people.
Nephrologist at the Menzies School of Health Research, Paul Lawton, said his research team had been investigating key causes that dramatically impact upon remote Aboriginal communities.
Senator Malarndirri McCarthy discusses her kidney diseaese and treatment by Dr Paul Lawton
A new approach to treatment is helping Indigenous Australians fight kidney disease